Last reviewed · How we verify
V81444
At a glance
| Generic name | V81444 |
|---|---|
| Sponsor | Vernalis (R&D) Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD) (PHASE1, PHASE2)
- A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease (PHASE1)
- A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V81444 CI brief — competitive landscape report
- V81444 updates RSS · CI watch RSS
- Vernalis (R&D) Ltd portfolio CI